Board of Directors of the company at its meeting held by today have inter alia considered, approved and taken on record the unaudited standalone financial statement of the company for the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
KMS Medisurgi Ltd's Board approved unaudited standalone results for H1 FY26 (ended Sept 30, 2025) on Nov 14, 2025. Revenue from operations fell to Rs 661.66 lakhs from Rs 781.38 lakhs in the same period last year — a decline of about 15%. Despite the drop in revenue, profit after tax jumped sharply to Rs 23.15 lakhs from Rs 7.88 lakhs YoY (nearly tripling), helped by lower raw material costs (Rs 507.65 lakhs vs Rs 630.34 lakhs) and reduced other expenses. Profit before tax rose to Rs 29.63 lakhs from Rs 10.45 lakhs. The auditor issued a qualified review report, flagging two concerns: post-employment benefits were accounted using an LIC group gratuity report instead of a proper actuarial valuation required under AS-15, and stock records are still being reconciled with books, leaving closing inventory of Rs 295.45 lakhs unverified. Operating cash flow was healthy at Rs 186.15 lakhs.
Weak top-line is a concern, but sharp profitability recovery and margin expansion are positives. The auditor's qualifications around accounting for employee benefits and the unreconciled inventory are red flags that warrant attention before drawing strong conclusions on the company's true financial position.